Abstract:Human angiotensin-I-converting enzyme (ACE) is an important target of antihypertensive therapy, which possesses a bulky, hydrophobic pocket that is physicochemically compatible with a wide variety of peptide substrates and small-molecule ligands. Rational design of potent ACE inhibitors has long been an attractive topic in the chemical, biological and medical communities. In the present study, an integrative protocol is described to optimize and modify peptides bound with ACE based on their complex three-dimensional structures. The protocol combines a number of sophisticated computational methods including molecular dynamics (MD) simulation, quantitative structure-activity relationship (QSAR), molecular mechanics/Poisson-Boltzmann surface area (MM-PB/SA) and quantum mechanics/molecular mechanics (QM/MM) to discover new potent ACE-inhibitory peptides. With this strategy hundreds of potential peptides are generated virtually, from which several promising candidates are synthesized and assayed in vitro using a standard Fmoc-protected amino acid solid phase synthesis and spectrophotometric method, respectively. Six peptides are found to have potency against ACE, four of which (LVY, VLKP, MLPVY and LKIPLY) show satisfactory inhibitory capability (pIC(50)=5.84, 5.27, 5.40 and 5.57, respectively). Subsequently, the complex structures of tripeptide LVY and hexapeptide LKIPLY with ACE are computationally modeled and their binding free energies are estimated as -34.2 and -57.8 kcal/mol, respectively, by using a rigorous QM/MM scheme. Intensive steric collisions are observed around the C-terminus of peptide ligands in the bound state. Based upon the findings the C-terminal residues of the two peptides are modified to small, hydrophobic amino acids Val and Ala, resulting in mutated peptides LVA and LKIPVA, respectively. Consequently, a significant improvement in ACE inhibitory activity is observed for the LKIPVA mutant (pIC(50) increases from 5.57 to 6.07), whereas only a modest activity change was associated with the LVA mutant (pIC(50) decreases from 5.84 to 5.80).

Molecular Modeling and Biological Effects of Peptidomimetic Inhibitors of TACE Activity.

Molecular Dynamics Optimization of a Computational Model of TACE and its Substrate Peptide

Comparison of Properties of Tumor Necrosis Factor-Α Converting Enzyme (TACE) and Some Matrix Metalloproteases (mmps) in Catalytic Domains

Definition of Peptide Inhibitors from a Synthetic Peptide Library by Targeting Gelatinase B/matrix Metalloproteinase-9 (MMP-9) and TNF-α Converting Enzyme (TACE/ADAM-17)

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Identification and Molecular Mechanism of Angiotensin-Converting Enzyme Inhibitory Peptides from Larimichthys Crocea Titin

TDPBP Derivative Aiding Liquid-Phase Synthesis Strategy and ACE Inhibitory Structure-activity Relationship of Anti-SARS Octapeptide

Novel Thiol-Based Tace Inhibitors: Rational Design, Synthesis, and Sar of Thiol-Containing Aryl Sulfonamides

Microwave-Assisted Solid-Phase Synthesis, Biological Evaluation and Molecular Docking of Angiotensin I-Converting Enzyme Inhibitors

Design, synthesis, and bioactivities of tasiamide B derivatives as cathepsin D inhibitors.

Integrating Computational Modeling and Experimental Assay to Discover New Potent Ace-Inhibitory Peptides

Detection of Biological Activity of Recombinant Human Tumor Necrosis Factor α Inhibitory Peptide Fused with Anti-Inflammatory Acidic Tail

Computational modeling of mast cell tryptase family informs selective inhibitor development

Design, Synthesis and Biological Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives As Aminopeptidase N/CD13 Inhibitors.

Design, Synthesis and Preliminary Activity Evaluation of Novel Peptidomimetics As Aminopeptidase N/CD13 Inhibitors

Discovery of Highly Potent Tnf Alpha Inhibitors Using Virtual Screen

Computational Design And Optimization Of Novel D-Peptide Tnf Alpha Inhibitors

IK682, a Tight Binding Inhibitor of TACE

Studies on the Bioactivities of ACE-inhibitory Peptides with Phenylalanine C-terminus Using 3D-QSAR, Molecular Docking and in Vitro Evaluation.

Protein Engineering of the Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Inhibitory Domain: IN SEARCH OF SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS

Discovery of Highly Potent TNFα Inhibitors Using Virtual Screen.